Gilead Sciences | Ventes



Sales Changement Date
AbbVie USD 13.34B 1.76B 2025-03
Agios Pharmaceuticals USD 8.7M 2.03M 2025-03
ALKERMES USD 306.5M 123.5M 2025-03
Alnylam Pharmaceuticals USD 594.19M 1.02M 2025-03
Amgen USD 8.15B 936M 2025-03
Biogen USD 2.43B 24.7M 2025-03
BioMarin Pharmaceutical USD 745M 2.31M 2025-03
Bristol-Myers Squibb USD 11.2B 1.14B 2025-03
Eli Lilly USD 12.73B 802.8M 2025-03
Gilead Sciences USD 6.67B 899M 2025-03
GlaxoSmithKline GBP 7.52B 600M 2025-03
Glaxosmithkline GBP 8.12B 105M 2024-12
Incyte USD 1.05B 128.7M 2025-03
J&J USD 21.89B 630M 2025-03
Merck USD 15.53B 94M 2025-03
Moderna USD 108M 858M 2025-03
Neurocrine Biosciences USD 572.6M 55.1M 2025-03
Novartis USD 13.15B 330M 2024-12
Pfizer USD 13.72B 4.04B 2025-03
PTC Therapeutics USD 190M 23.17M 2025-03
Regeneron Pharmaceuticals USD 3.03B 760M 2025-03
Sanofi EUR 9.9B 660M 2025-03
Sarepta Therapeutics USD 774.9M 116.49M 2025-03
United Therapeutics USD 794.4M 58.5M 2025-03
Vertex Pharmaceuticals USD 2.77B 142M 2025-03



Gilead Sciences Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.